Pediatric Exclusivity Will Not Irreparably Harm Generics, Judge Rules
This article was originally published in The Tan Sheet
Executive Summary
Exclusivity extensions under the FDA Modernization Act's pediatric provisions will not cause "irreparable harm" to generic drug manufacturers, D.C. federal court Judge James Robertson rules in an April 20 decision denying a generics industry motion for a preliminary injunction.